Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the price of GSK American Depositary Shares (ADSs) at $49.10 per ADS on August 29, 2014, used for the revaluation of a notional investment.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a specific increase in the notional allocation of 3 ADSs for Dr. K. Slaoui (a connected person of Dr. M. Slaoui) resulting from the revaluation of the cash element within the GSK 401K plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a connected person's transaction.
Key Facts for Investor Verification
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan.
- Connected Person: Dr. K. Slaoui (Connected person of Dr. M. Slaoui).
- Volume: 3 ADSs.
- Valuation Date: August 29, 2014.
- Share Price: $49.10 per ADS.
- Reporting Date: September 2, 2014.